Find valuable ACTEMRA® (tocilizumab) information, including an ACTEMRA® dosing calculator, RA patient brochure, ACTEMRA® prescription guide and the. Find information about ACTEMRA® (tocilizumab) patient monitoring and management, Please see full Prescribing Information, including Boxed WARNING. Actemra® (tocilizumab) pre-filled syringe for subcutaneous (SC) injection. Patients Consumer Medicine Information (CMI). Healthcare Professionals.
|Genre:||Health and Food|
|Published (Last):||10 July 2006|
|PDF File Size:||8.46 Mb|
|ePub File Size:||20.26 Mb|
|Price:||Free* [*Free Regsitration Required]|
Print this section Print the entire contents of. The above information is provided for general informational and educational purposes only.
Administer first SC dose instead of the next scheduled IV dose. Actemra prescribing information animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. Actwmra Administration Indicated only in adults with rheumatoid arthritis Rotate SC injection sites ie, thighs, abdomen, outer area of upper arm [caregiver only] and inject full amount of the syringe 0. In patients who develop an ANC less actemra prescribing information per mm 3 treatment is not recommended.
Genentech does not recommend and does not endorse the content on any third-party websites.
Medication Guide: Tocilizumab (Actemra)
Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling Maternal immunoglobulin G IgG is present in human milk; if tocilizumab is transferred into human milk, effects of local exposure in gastrointestinal actemraa and potential limited systemic exposure in infant to tocilizumab are unknown.
Tell your healthcare provider actemra prescribing information you are planning to become pregnant, are pregnant, plan to breast-feed, or are breast-feeding.
The most common events observed were nasopharyngitis and upper respiratory tract infections. Do you need help? Denosumab Prolia Medication Guide: Thanks for sharing this page. Pre-Infusion Checklist Confirm the following: Has a current or recent infection or illness.
Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis TBbacterial, invasive fungal, viral, or other opportunistic infections.
These ISRs occurred in a greater proportion of patients at or above 30 kg Do not administer as an intravenous push or bolus. Quantity Actemra prescribing information Drugs that have quantity limits associated with each prescription. In SC-II, the frequency of injection-site reactions actemra prescribing information 7.
FDA Internet Application Site (Accessdata) Error
In the actemra prescribing information extension over an average duration of 73 weeks of treatment, the overall rate of infections was per patient-years. Infliximab Remicade Medication Guide: ACTEMRA is indicated for the treatment of active systemic juvenile idiopathic arthritis in patients 2 years of age and older. If a serious infection develops, interrupt tocilizumab until the infection is controlled.
See National Cholesterol Educational Program. SC Dosing Patients weighing less than kg: Contact immediately, as well as your healthcare provider or nurse, if you experience any of these reactions: Impact of treatment actemra prescribing information tocilizumab on demyelinating disorders is unknown, but multiple sclerosis and chronic catemra demyelinating polyneuropathy were reported rarely in RA clinical studies; monitor actemra prescribing information signs and symptoms potentially indicative of demyelinating disorders.
Dose interruptions are recommended for informatio enzyme abnormalities, low neutrophil counts, and low platelet counts in patients with PJIA and SJIA at levels similar to what is outlined for adults with RA.
Tell your healthcare provider right away if you see any signs of these symptoms:. For more severe reactions such as hives, difficulty breathing, chest pain, high or low blood pressure, swelling of face and hands, fever, chills or anaphylaxis or when actemra prescribing information reactions persist despite slowing the infusion, stop the infusion and treat the acute reaction.
Patients with invasive fungal infections may present with disseminated, rather than localized, disease. Non-Medicare Plans Medicare Plans. Risks involved outweigh potential benefits. Infusion Informatuon In PJIA patients, infusion-related reactions are defined as all events occurring during or within 24 hours of an infusion.
This drug is available at a middle level co-pay. Two additional patients developed MAS during the long-term extension. Tell your healthcare provider right away if you actemra prescribing information any prescribig these side effects: Prescribers should exercise caution in considering the use of ACTEMRA in patients with preexisting or recent-onset demyelinating disorders.
IV Preparation Withdraw a volume of 0.
Actemra (tocilizumab) dosing, indications, interactions, adverse effects, and more.
Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ACTEMRA, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Precribing information does not take peescribing place of talking with your healthcare provider about your medical actemra prescribing information or your treatment.
Two heavy chain and two light chain polypeptides are linked by intra- and inter-molecular disulfide bonds. Click “OK” if you are a healthcare professional. Contact the applicable plan provider for the most current information. ACTEMRA is an immunosuppressant, and treatment with immunosuppressants may result actemra prescribing information an actemra prescribing information risk of malignancies.
Dilute informaiton mL in 0. Positive evidence of human fetal risk. The risks and benefits of treatment with ACTEMRA should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Demyelinating Disorders The impact of treatment with ACTEMRA on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies.
Thanks for sharing this page. Increased frequency and magnitude of these elevations was observed when potentially hepatotoxic drugs e. Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Your healthcare provider should do blood tests to check your cholesterol levels 4 to 8 weeks after you start receiving ACTEMRA, and then every 6 months after that You should not receive ACTEMRA if your neutrophil and platelet counts are too low or your liver function test levels are too high.
The limited available data with ACTEMRA in actemra prescribing information women are not sufficient to determine whether there actemra prescribing information a drug-associated risk for major birth defects and miscarriage.